RN Mobile Menu

Search form


Drug Development

Drug Development


The FDA has nixed Eli Lilly's and Inctye's application for baricitinib in its current form asking for additional safety and clinical data.

HFF Rituxan 500mg (©Genentech)

Designated a breakthrough therapy for pemphigus vulgaris, rituximab has been shown to work better than prednisone alone and with fewer adverse events, researchers report in The Lancet.


In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.


Ixekizumab, one of three anti-IL-17 agents for moderate-to-severe plaque psoriasis, has been approved by the FDA for plaque psoriasis — a disease that goes untreated for most patients.

Subscribe to Drug Development on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.